Researchers at the University of Missouri have found that rapamycin, a drug commonly used to prevent organ transplant rejection, may help protect against Alzheimer’s disease in individuals at increased risk. The study, led by Professor Ai-Ling Lin, focused on middle-aged adults carrying the APOE4 gene variant, which is linked to a higher likelihood of developing Alzheimer’s. The findings suggest that rapamycin can improve blood flow in the brains of these individuals, potentially addressing early signs of Alzheimer’s before symptoms manifest.
Rapamycin Improves Brain Blood Flow in APOE4 Carriers
In the study, healthy adults aged 45 to 65, including those with and without the APOE4 variant, were administered a low daily dose of rapamycin for four weeks. Results showed that participants with the APOE4 variant experienced significant improvements in brain blood flow, while those without the variant did not exhibit similar benefits. This indicates that rapamycin may be particularly effective for individuals genetically predisposed to Alzheimer’s.
Gender Differences in Treatment Response
The researchers also noted that women carrying the APOE4 variant showed the most substantial improvements in brain circulation following treatment. This finding is significant, as women represent nearly two-thirds of the Alzheimer’s population. Lin emphasized the importance of precision medicine in this context, stating, “We also found that females with APOE4 saw the greatest improvement in brain blood flow, which is significant given that nearly two-thirds of people with Alzheimer’s are women.”
Background on Alzheimer’s Disease and APOE4
Alzheimer’s disease is the most common form of dementia, characterized by memory loss and cognitive decline. The APOE4 gene variant is known to increase the risk of developing the disease, as it can lead to reduced blood flow in certain brain areas long before noticeable symptoms appear. Identifying early interventions, such as the use of rapamycin, could be crucial in mitigating the impact of Alzheimer’s on those at risk.
The next steps for this research involve further studies to determine if rapamycin can prevent Alzheimer’s or help maintain memory function over time. Lin’s work continues to contribute to the understanding of Alzheimer’s and potential preventive strategies.
